Childhood psychiatric disorders

Supernus Announces Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 4, 2021

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Key Points: 
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
  • Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinsons disease, cervical dystonia and chronic sialorrhea.
  • This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

Retrieved on: 
Wednesday, July 21, 2021

The U.S. commercial launch of AZSTARYS is a significant milestone for KemPharm and an important advancement in the treatment of ADHD, a disease indication that has seen little innovation in recent years, said Travis C. Mickle, Ph.D., President and CEO of KemPharm.

Key Points: 
  • The U.S. commercial launch of AZSTARYS is a significant milestone for KemPharm and an important advancement in the treatment of ADHD, a disease indication that has seen little innovation in recent years, said Travis C. Mickle, Ph.D., President and CEO of KemPharm.
  • Since the FDAs approval of AZSTARYS in March, the various teams across Corium have been working diligently to ready AZSTARYS for its U.S. launch.
  • We believe Corium has built a best-in-class commercial organization, and as a result, we expect the market potential for AZSTARYS will be maximized.
  • AZSTARYS is an FDA-approved, once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years or older.

Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering

Retrieved on: 
Tuesday, July 20, 2021

Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”), today announced the closing of its initial public offering (the “Offering”) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.

Key Points: 
  • Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the closing of its initial public offering (the Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.
  • The Company received aggregate gross proceeds of $21.9 million from the Offering, before deducting underwriting discounts and other related expenses.
  • Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD.
  • All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Companys proposed Offering.

Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering

Retrieved on: 
Thursday, July 15, 2021

Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the pricing of its initial public offering (Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share.

Key Points: 
  • Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the pricing of its initial public offering (Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share.
  • Regencell expects to receive aggregate gross proceeds of approximately $21.9 million from this Offering, before deducting underwriting discounts and other related expenses.
  • The Offering is expected to close on or about July 20, 2021, subject to the satisfaction of customary closing conditions.
  • Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD.

Russell E. Scheffer, MD is recognized by Continental Who's Who

Retrieved on: 
Tuesday, July 13, 2021

Russell E. Scheffer, MD is a board-certified psychiatrist with 30 years of academic and clinical excellence.

Key Points: 
  • Russell E. Scheffer, MD is a board-certified psychiatrist with 30 years of academic and clinical excellence.
  • He has garnered a well-deserving reputation among the Best Doctors in America since 2005 for his devotion to his patients.
  • Dr. Scheffer serves as the medical director within Cigna Healthcare, a global health service company, where he consults and reviews policies.
  • Additionally, Dr. Scheffer operates a small private practice specializing in child, adolescent, and family psychiatry, bipolar disorder, psychotic disorders, ADHD, and more.

Drug Relieves Persistent Daydreaming, Fatigue, and Brain Sluggishness in Adults with ADHD

Retrieved on: 
Tuesday, June 29, 2021

Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.

Key Points: 
  • Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.
  • The NYU Langone-Mount Sinai team's findings, he adds, are the first to show that such treatments also work in adults.
  • "These findings highlight the importance of assessing symptoms of sluggish cognitive tempo and executive brain function in patients when they are initially diagnosed with ADHD," says Adler.
  • Researchers then carefully tracked their psychiatric health on a weekly basis through standardized tests for signs and symptoms of sluggish cognitive tempo, ADHD, as well as other measures of brain function.

M&T Bank and Life-Skills App Magnusmode Collaborate to Support Customers with Autism, Cognitive and Intellectual Disabilities

Retrieved on: 
Tuesday, June 15, 2021

"We are excited to work with Magnusmode not only because they're an inspiring local startup, but also because their product is incredibly intuitive and well-designed to support our customers."

Key Points: 
  • "We are excited to work with Magnusmode not only because they're an inspiring local startup, but also because their product is incredibly intuitive and well-designed to support our customers."
  • Using digitalized "Card Decks," the MagnusCards app guides users through tasks and activities that might otherwise feel challenging or overwhelming.
  • The app's users include people with autism, down syndrome, acquired brain injury, dementia, ADHD and other cognitive disabilities.
  • "Confusing or complex services can create barriers for people with autism and other cognitive disabilities.

Smart Kids with Learning Disabilities Announces the 2021 Fred J. Epstein Youth Achievement Award Winners

Retrieved on: 
Tuesday, June 15, 2021

NORWALK, Conn., June 15, 2021 /PRNewswire-PRWeb/ -- The 2021 Fred J Epstein Youth Achievement Awards (YAA) were presented at the Smart Kids with Learning Disabilities annual benefit on Thursday, May 13th 2021.

Key Points: 
  • NORWALK, Conn., June 15, 2021 /PRNewswire-PRWeb/ -- The 2021 Fred J Epstein Youth Achievement Awards (YAA) were presented at the Smart Kids with Learning Disabilities annual benefit on Thursday, May 13th 2021.
  • The award, named for pioneering pediatric neurosurgeon Dr. Fred J Epstein, recognizes outstanding achievements by young people with learning disabilities (LD) and ADHD.
  • Dr. Epstein credited his significant learning disabilities as a major factor in his success and became an inspiration to children with LD.
  • She maintained a higher than 4.0 GPA and has excelled in online coursework certifications, including Psychotherapy, Cognitive-Behavioral Therapy and Psych diagnostics.

New Study Finds ADHD Test Serves as a Better Indicator of Medication Effects

Retrieved on: 
Tuesday, June 8, 2021

The Quantified Behavioral Test (QbTest), serves as a better early indicator of treatment effects for ADHD, confirming that healthcare professionals can confidently use objective data alongside patient feedback regarding treatment effectiveness.

Key Points: 
  • The Quantified Behavioral Test (QbTest), serves as a better early indicator of treatment effects for ADHD, confirming that healthcare professionals can confidently use objective data alongside patient feedback regarding treatment effectiveness.
  • View the full release here: https://www.businesswire.com/news/home/20210608005305/en/
    Study finds ADHD test serves as a better early indicator of medication effects than rating scales (Graphic: Business Wire)
    Clinical ADHD treatment procedures typically involve self-rated evaluations of symptoms as a means for measuring medication effects in adults with ADHD.
  • At the first follow up, QbTests activity and inattention measures showed significant effect of medication, compared to ASRS, that indicated only moderate effect.
  • The study proves how important it is to have objective data when managing ADHD symptoms.

ADHD Medications Associated with Reduced Risk of Suicidality in Children with Significant Behavioral Symptoms

Retrieved on: 
Friday, June 4, 2021

"Early diagnosis and treatment of behavioral symptoms with ADHD medication, particularly among children with severe externalizing symptoms, may serve not only to improve learning and behavior problems, but also to decrease suicidality risk."

Key Points: 
  • "Early diagnosis and treatment of behavioral symptoms with ADHD medication, particularly among children with severe externalizing symptoms, may serve not only to improve learning and behavior problems, but also to decrease suicidality risk."
  • The researchers found that children expressing suicidal tendencies had more externalizing symptoms and were more likely to receive ADHD medication than non-suicidal children.
  • However, among children who demonstrated significant externalizing behaviors, those taking ADHD medications had lesser odds for suicidality, suggesting a moderating role for ADHD medications in these children.
  • They found that children with high externalizing symptoms who were treated with ADHD medications at baseline were less likely to be suicidal one year later.